Institute for Cancer Genetics and Informatics - ICGI

Hjem
Norge
Oslo
Institute for Cancer Genetics and Informatics - ICGI

Institute for Cancer Genetics and Informatics at Oslo University Hospital, Norway. Performing resear from 2016 - 2021.

This is the official page for the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital. A joint team of researchers, developers and lab-personnel have for more than 20 years been developing methods to improve cancer diagnostics through combining biomedicine and informatics. In recent years, we have focused on new technologies, often referred to as artificial intelligence (AI). We are located at the Radium Hospital as part of the Comprehensive Cancer Centre at Oslo University Hospital. The Institute has also been part of Centre for Cancer Biomedicine, appointed Centre for excellence in research by the Norwegian Research Council, and headed the Norwegian Research Council Lighthouse Project Domore! The Institute’s work consistently supports the high international standing of the Oslo University Hospital, both through our contribution to medical services and through our research contribution. We hope you will find information about our ongoing projects and engage in our work. Unwanted comments will, however, be removed.

24/11/2025

Våre kolleger har representert instituttet på onkologisk forum i Trondheim!

16/06/2025

Vår forskningsleder Andreas Kleppe er tildelt midler for banebrytende forskning på digitalpatologi og kunstig intelligens. Les artikkel på Oslo universitetssykehus' nettsider:
https://www.oslo-universitetssykehus.no/avdelinger/kreftklinikken/institutt-for-kreftgenetikk-og-informatikk/FRIPRO-midler-til-Andreas-Kleppe/

13/05/2025

⏰ This post is a bit late – but our team certainly wasn’t during Holmenkollstafetten this year! 😄

The Institute for Cancer Genetics and Informatics (with a boost of running power from DoMore Diagnostics💪) joined a whole load of teams from Oslo universitetssykehus, running faster than ever before! Thanks to a wisely chosen t-shirt colour and nearly flawless handovers, we pulled off the near-impossible: no one got lost in a crowd of 75,000 people!

All sections at ICGI were represented, and the atmosphere in the city of Oslo was electric. We almost earned a medal – but a heroic last-minute substitution (a woman stepping in for an ill male runner) meant we couldn’t change our race category, so the tougher time requirement was just out of reach. Still, we finished strong, and the team spirit was unbeatable 💃🏃‍♂️

Rumour has it several colleagues are already eager to join next year’s team – so selection and training for 2026 starts now! Time to lace up!

Kreftlex

21/02/2025

Great days here in Rome attending the European Society of Gynaecological Oncology - ESGO and ENITEC meetings. Today Dr. Manohar Pradhan presented our research on Prognostic value of different stages of maturation of tertiary lymphoid structures in molecular subgroups in endometrial carcinoma.

Kildal, Askautrud, Lindemann, , , Oslo universitetssykehus

11/02/2025

We are honoured to be part of the NEXTMAP project, recently mentioned in Dagens Medisin. Alongside our esteemed partners, ICGI is dedicated to harnessing AI for cancer prevention and treatment.

Norge kan redde millioner av liv og setter Europa i front i kampen mot kreft – hvis vi våkner opp av dvalen i tide.

06/02/2025

Takk til Histoteknikerforeningen for flott seminar! Interessante foredrag, velorganisert, nyttig erfaringsutveksling og god mat. Alltid gøy med ny innsikt og gode kolleger.

03/02/2025

Patients with advanced/recurrent endometrial carcinoma have poor outcomes. Molecular classification can help in prognostication, even for advanced stages.

The current implementation of immunotherapy in addition to chemotherapy is expected to significantly improve outcomes for these patients, particularly those with mismatch repair deficient advanced/recurrent disease.

See our article in the International Journal of Gynecological Cancer for details: https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(24)22171-X/fulltext

18/11/2024

Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer

This article published in the journal Gynecologic Oncology last Friday, sheds new light on the role of L1CAM, in high-risk endometrial cancer. The article is the result of a collaboration between the Institute of Cancer Genetics and Informatics and the Department of Surgical Oncology, Section for Gynecological Oncology, at Oslo University Hospital, supported by a grant from the Norwegian Cancer Society.

Highlights
• Clearer role of molecular classification and L1CAM in high-risk endometrial cancer.
•ProMisE independently predicted time to recurrence, not cancer-specific survival.
•Patients with POLE mutated tumors had an excellent prognosis.
•L1CAM overexpression was a strong, independent marker for recurrence and survival.
•L1CAM overexpression was related to distant recurrences for the p53 and NSMP group.

Since L1CAM is an additional adverse factor in the p53 abnormal and NSMP groups. These groups need special attention in studies intensifying adjuvant treatment.

, Oslo universitetssykehus, Kreftforeningen, Gynkreftforeningen, European Society of Gynaecological Oncology - ESGO
Andreas Kleppe, Kristina Lindemann, Wanja Kildal, Kari Anne Tobin, Manohar Pradhan, Ljiljana Vlatkovic, Maria Xepapdakis Isaksen, Håvard E. Danielsen, Hanne Askautrud, Gunnar Kristensen

https://www.gynecologiconcology-online.net/article/S0090-8258(24)01202-2/fulltext

26/09/2024

På IKI tar vi vare på hverandre❤️ved blant annet å delta på kurs i praktisk hjerte- lungeredning. Takk til gode (interne) instruktører!🧡💚💜💪

Oslo universitetssykehus

09/09/2024

🎉 Congratulations to the Institute for Cancer Research on their 70th anniversary! 🧬🔬

We celebrate this significant milestone in cancer research and we thank you for this opportunity to come together at the celebration symposium. It’s a wonderful opportunity to share ideas and nurture new collaborations. Here’s to our continued efforts in the fight against cancer.

Oslo universitetssykehus

https://ous-research.no/home/institute/Homepage%20news/25547

Adresse

Ullernchausséen
Oslo
0379

Nettsted

http://icgi.no/

Varslinger

Vær den første som vet og la oss sende deg en e-post når Institute for Cancer Genetics and Informatics - ICGI legger inn nyheter og kampanjer. Din e-postadresse vil ikke bli brukt til noe annet formål, og du kan når som helst melde deg av.

Kontakt Praksisen

Send en melding til Institute for Cancer Genetics and Informatics - ICGI:

Snarveier

Vil du plassere din praksis på toppen av Klinikk-listen i Oslo?

Del

Type

Medisinsk laboratorium

A specialized Cancer Research Institute at Oslo University Hospital

This is the official page for the Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital. The ICGI brings scientists, researchers, patients, pathologists, developers, consultants, doctors and suppliers together in an environment of cooperation and sharing — to research and develop the concepts needed to improve cancer care, research and treatment. We are located at the Radium Hospital as part of the Comprehensive Cancer Centre at Oslo University Hospital. The Institute heads the DoMore! project, one of the Norwegian Research Council’s Lighthouse projects within medicine and IT. The Institute’s work consistently supports the high international standing of the Oslo University Hospital, both through our contribution to medical services and through our research contribution. Covering a wide field from clinical databases to image analysis and robotic surgery, medical informatics has become an inherent part of most medical disciplines. Medical informatics incorporate and integrate research, clinical care and public health to enable everyone to be supported by informatics-based information and communication systems and technologies. We hope you will find information about our ongoing projects and engage in our work. Unwanted comments will, however, be removed.